APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Granulocytes Monoclonal Antibody

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Granulocytes Monoclonal Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173996280322 December 2025194 pages

Choose your research edition.

Industry ResearchGranulocytes Monoclonal Antibody Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocytes Monoclonal Antibody Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Granulocytes Monoclonal Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocytes Monoclonal Antibody Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocytes Monoclonal Antibody Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Granulocytes Monoclonal Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Granulocytes Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocytes Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocytes Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Granulocytes Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Granulocytes Monoclonal Antibody include Abbexa, Assay Genie, Biomatik, Boster Biological Technology, CLOUD-CLONE CORP., CUSABIO, Innovative Research, LifeSpan BioSciences, Inc and MyBiosource, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulocytes Monoclonal Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocytes Monoclonal Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocytes Monoclonal Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulocytes Monoclonal Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulocytes Monoclonal Antibody Segment by Company

Abbexa

Assay Genie

Biomatik

Boster Biological Technology

CLOUD-CLONE CORP.

CUSABIO

Innovative Research

LifeSpan BioSciences, Inc

MyBiosource, Inc.

ZodelBiotec Ltd.

RayBiotech, Inc.

Thermo Fisher

Shanghai Korain Biotech Co., Ltd.

Wuhan Fine Biotech Co., Ltd.

Granulocytes Monoclonal Antibody Segment by Type

Recombinant

Non-recombinant

Granulocytes Monoclonal Antibody Segment by Application

Immunofluorescence

Immunoprecipitation

ELISA

Flow Cytometry

Western Blot

Other

Granulocytes Monoclonal Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocytes Monoclonal Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocytes Monoclonal Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocytes Monoclonal Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulocytes Monoclonal Antibody market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Granulocytes Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Granulocytes Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Granulocytes Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Granulocytes Monoclonal Antibody Industry Trends Table 2. Granulocytes Monoclonal Antibody Industry Drivers Table 3. Granulocytes Monoclonal Antibody Industry Opportunities and Challenges Table 4. Granulocytes Monoclonal Antibody Industry Restraints Table 5. Global Granulocytes Monoclonal Antibody Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Granulocytes Monoclonal Antibody Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Granulocytes Monoclonal Antibody Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Granulocytes Monoclonal Antibody Sales Market Share by Manufacturers Table 9. Global Granulocytes Monoclonal Antibody Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Granulocytes Monoclonal Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Granulocytes Monoclonal Antibody Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Granulocytes Monoclonal Antibody Manufacturers, Product Type & Application Table 13. Global Granulocytes Monoclonal Antibody Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulocytes Monoclonal Antibody by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Recombinant Table 17. Major Manufacturers of Non-recombinant Table 18. Global Granulocytes Monoclonal Antibody Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Granulocytes Monoclonal Antibody Sales by Type (2021-2026) & (k units) Table 20. Global Granulocytes Monoclonal Antibody Sales by Type (2027-2032) & (k units) Table 21. Global Granulocytes Monoclonal Antibody Sales Market Share by Type (2021-2026) Table 22. Global Granulocytes Monoclonal Antibody Sales Market Share by Type (2027-2032) Table 23. Global Granulocytes Monoclonal Antibody Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Granulocytes Monoclonal Antibody Revenue by Type (2021-2026) & (k units) Table 25. Global Granulocytes Monoclonal Antibody Revenue by Type (2027-2032) & (k units) Table 26. Global Granulocytes Monoclonal Antibody Revenue Market Share by Type (2021-2026) Table 27. Global Granulocytes Monoclonal Antibody Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Immunofluorescence Table 29. Major Manufacturers of Immunoprecipitation Table 30. Major Manufacturers of ELISA Table 31. Major Manufacturers of Flow Cytometry Table 32. Major Manufacturers of Western Blot Table 33. Major Manufacturers of Other Table 34. Global Granulocytes Monoclonal Antibody Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Granulocytes Monoclonal Antibody Sales by Application (2021-2026) & (k units) Table 36. Global Granulocytes Monoclonal Antibody Sales by Application (2027-2032) & (k units) Table 37. Global Granulocytes Monoclonal Antibody Sales Market Share by Application (2021-2026) Table 38. Global Granulocytes Monoclonal Antibody Sales Market Share by Application (2027-2032) Table 39. Global Granulocytes Monoclonal Antibody Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Granulocytes Monoclonal Antibody Revenue by Application (2021-2026) & (k units) Table 41. Global Granulocytes Monoclonal Antibody Revenue by Application (2027-2032) & (k units) Table 42. Global Granulocytes Monoclonal Antibody Revenue Market Share by Application (2021-2026) Table 43. Global Granulocytes Monoclonal Antibody Revenue Market Share by Application (2027-2032) Table 44. Global Granulocytes Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Granulocytes Monoclonal Antibody Sales by Region (2021-2026) & (k units) Table 46. Global Granulocytes Monoclonal Antibody Sales Market Share by Region (2021-2026) Table 47. Global Granulocytes Monoclonal Antibody Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Granulocytes Monoclonal Antibody Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Granulocytes Monoclonal Antibody Sales by Country (2021-2026) & (k units) Table 51. North America Granulocytes Monoclonal Antibody Sales by Country (2027-2032) & (k units) Table 52. Europe Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Granulocytes Monoclonal Antibody Sales by Country (2021-2026) & (k units) Table 54. Europe Granulocytes Monoclonal Antibody Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Granulocytes Monoclonal Antibody Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Granulocytes Monoclonal Antibody Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Granulocytes Monoclonal Antibody Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Granulocytes Monoclonal Antibody Sales by Country (2027-2032) & (k units) Table 61. Global Granulocytes Monoclonal Antibody Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Granulocytes Monoclonal Antibody Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Granulocytes Monoclonal Antibody Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Granulocytes Monoclonal Antibody Revenue Market Share by Region (2021-2026) Table 65. Global Granulocytes Monoclonal Antibody Revenue Market Share by Region (2027-2032) Table 66. Abbexa Company Information Table 67. Abbexa Business Overview Table 68. Abbexa Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Abbexa Granulocytes Monoclonal Antibody Product Portfolio Table 70. Abbexa Recent Development Table 71. Assay Genie Company Information Table 72. Assay Genie Business Overview Table 73. Assay Genie Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Assay Genie Granulocytes Monoclonal Antibody Product Portfolio Table 75. Assay Genie Recent Development Table 76. Biomatik Company Information Table 77. Biomatik Business Overview Table 78. Biomatik Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biomatik Granulocytes Monoclonal Antibody Product Portfolio Table 80. Biomatik Recent Development Table 81. Boster Biological Technology Company Information Table 82. Boster Biological Technology Business Overview Table 83. Boster Biological Technology Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Boster Biological Technology Granulocytes Monoclonal Antibody Product Portfolio Table 85. Boster Biological Technology Recent Development Table 86. CLOUD-CLONE CORP. Company Information Table 87. CLOUD-CLONE CORP. Business Overview Table 88. CLOUD-CLONE CORP. Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. CLOUD-CLONE CORP. Granulocytes Monoclonal Antibody Product Portfolio Table 90. CLOUD-CLONE CORP. Recent Development Table 91. CUSABIO Company Information Table 92. CUSABIO Business Overview Table 93. CUSABIO Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. CUSABIO Granulocytes Monoclonal Antibody Product Portfolio Table 95. CUSABIO Recent Development Table 96. Innovative Research Company Information Table 97. Innovative Research Business Overview Table 98. Innovative Research Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Innovative Research Granulocytes Monoclonal Antibody Product Portfolio Table 100. Innovative Research Recent Development Table 101. LifeSpan BioSciences, Inc Company Information Table 102. LifeSpan BioSciences, Inc Business Overview Table 103. LifeSpan BioSciences, Inc Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. LifeSpan BioSciences, Inc Granulocytes Monoclonal Antibody Product Portfolio Table 105. LifeSpan BioSciences, Inc Recent Development Table 106. MyBiosource, Inc. Company Information Table 107. MyBiosource, Inc. Business Overview Table 108. MyBiosource, Inc. Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. MyBiosource, Inc. Granulocytes Monoclonal Antibody Product Portfolio Table 110. MyBiosource, Inc. Recent Development Table 111. ZodelBiotec Ltd. Company Information Table 112. ZodelBiotec Ltd. Business Overview Table 113. ZodelBiotec Ltd. Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. ZodelBiotec Ltd. Granulocytes Monoclonal Antibody Product Portfolio Table 115. ZodelBiotec Ltd. Recent Development Table 116. RayBiotech, Inc. Company Information Table 117. RayBiotech, Inc. Business Overview Table 118. RayBiotech, Inc. Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. RayBiotech, Inc. Granulocytes Monoclonal Antibody Product Portfolio Table 120. RayBiotech, Inc. Recent Development Table 121. Thermo Fisher Company Information Table 122. Thermo Fisher Business Overview Table 123. Thermo Fisher Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Thermo Fisher Granulocytes Monoclonal Antibody Product Portfolio Table 125. Thermo Fisher Recent Development Table 126. Shanghai Korain Biotech Co., Ltd. Company Information Table 127. Shanghai Korain Biotech Co., Ltd. Business Overview Table 128. Shanghai Korain Biotech Co., Ltd. Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Shanghai Korain Biotech Co., Ltd. Granulocytes Monoclonal Antibody Product Portfolio Table 130. Shanghai Korain Biotech Co., Ltd. Recent Development Table 131. Wuhan Fine Biotech Co., Ltd. Company Information Table 132. Wuhan Fine Biotech Co., Ltd. Business Overview Table 133. Wuhan Fine Biotech Co., Ltd. Granulocytes Monoclonal Antibody Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Wuhan Fine Biotech Co., Ltd. Granulocytes Monoclonal Antibody Product Portfolio Table 135. Wuhan Fine Biotech Co., Ltd. Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Granulocytes Monoclonal Antibody Distributors List Table 139. Granulocytes Monoclonal Antibody Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Granulocytes Monoclonal Antibody Product Image Figure 2. Global Granulocytes Monoclonal Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocytes Monoclonal Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Granulocytes Monoclonal Antibody Sales (2021-2032) & (k units) Figure 5. Global Granulocytes Monoclonal Antibody Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Granulocytes Monoclonal Antibody Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Recombinant Image Figure 9. Non-recombinant Image Figure 10. Global Granulocytes Monoclonal Antibody Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Granulocytes Monoclonal Antibody Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Granulocytes Monoclonal Antibody Sales Market Share by Type (2021-2032) Figure 13. Global Granulocytes Monoclonal Antibody Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Granulocytes Monoclonal Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Granulocytes Monoclonal Antibody Revenue Market Share by Type (2021-2032) Figure 16. Immunofluorescence Image Figure 17. Immunoprecipitation Image Figure 18. ELISA Image Figure 19. Flow Cytometry Image Figure 20. Western Blot Image Figure 21. Other Image Figure 22. Global Granulocytes Monoclonal Antibody Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Granulocytes Monoclonal Antibody Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Granulocytes Monoclonal Antibody Sales Market Share by Application (2021-2032) Figure 25. Global Granulocytes Monoclonal Antibody Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Granulocytes Monoclonal Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Granulocytes Monoclonal Antibody Revenue Market Share by Application (2021-2032) Figure 28. North America Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Granulocytes Monoclonal Antibody Sales Market Share by Country (2021-2032) Figure 30. U.S. Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Granulocytes Monoclonal Antibody Sales Market Share by Country (2021-2032) Figure 35. Germany Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Granulocytes Monoclonal Antibody Sales Market Share by Country (2021-2032) Figure 42. China Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Granulocytes Monoclonal Antibody Sales Market Share by Country (2021-2032) Figure 50. Brazil Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Granulocytes Monoclonal Antibody Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Granulocytes Monoclonal Antibody Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Granulocytes Monoclonal Antibody Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Granulocytes Monoclonal Antibody Revenue (2021-2032) & (US$ Million) Figure 61. North America Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Granulocytes Monoclonal Antibody Revenue (2021-2032) & (US$ Million) Figure 63. Europe Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Granulocytes Monoclonal Antibody Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Granulocytes Monoclonal Antibody Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Granulocytes Monoclonal Antibody Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Granulocytes Monoclonal Antibody Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant
  • Non-recombinant
Applications
  • Immunofluorescence
  • Immunoprecipitation
  • ELISA
  • Flow Cytometry
  • Western Blot
  • Other
Companies covered
  • Abbexa
  • Assay Genie
  • Biomatik
  • Boster Biological Technology
  • CLOUD-CLONE CORP.
  • CUSABIO
  • Innovative Research
  • LifeSpan BioSciences, Inc
  • MyBiosource, Inc.
  • ZodelBiotec Ltd.
  • RayBiotech, Inc.
  • Thermo Fisher
  • Shanghai Korain Biotech Co., Ltd.
  • Wuhan Fine Biotech Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Granulocytes Monoclonal Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Granulocytes Monoclonal Antibody Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Granulocytes Monoclonal Antibody Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Granulocytes Monoclonal Antibody Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Granulocytes Monoclonal Antibody Market Dynamics
  1. 2.1 Granulocytes Monoclonal Antibody Industry Trends
  2. 2.2 Granulocytes Monoclonal Antibody Industry Drivers
  3. 2.3 Granulocytes Monoclonal Antibody Industry Opportunities and Challenges
  4. 2.4 Granulocytes Monoclonal Antibody Industry Restraints
3 Granulocytes Monoclonal Antibody Market by Manufacturers
  1. 3.1 Global Granulocytes Monoclonal Antibody Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Granulocytes Monoclonal Antibody Sales by Manufacturers (2021-2026)
  3. 3.3 Global Granulocytes Monoclonal Antibody Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Granulocytes Monoclonal Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Granulocytes Monoclonal Antibody Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Granulocytes Monoclonal Antibody Manufacturers, Product Type & Application
  7. 3.7 Global Granulocytes Monoclonal Antibody Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Granulocytes Monoclonal Antibody Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Granulocytes Monoclonal Antibody Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Granulocytes Monoclonal Antibody Tier 1, Tier 2, and Tier 3
4 Granulocytes Monoclonal Antibody Market by Type
  1. 4.1 Granulocytes Monoclonal Antibody Type Introduction
  2. 4.1.1 Recombinant
  3. 4.1.2 Non-recombinant
  4. 4.2 Global Granulocytes Monoclonal Antibody Sales by Type
  5. 4.2.1 Global Granulocytes Monoclonal Antibody Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Granulocytes Monoclonal Antibody Sales by Type (2021-2032)
  7. 4.2.3 Global Granulocytes Monoclonal Antibody Sales Market Share by Type (2021-2032)
  8. 4.3 Global Granulocytes Monoclonal Antibody Revenue by Type
  9. 4.3.1 Global Granulocytes Monoclonal Antibody Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Granulocytes Monoclonal Antibody Revenue by Type (2021-2032)
  11. 4.3.3 Global Granulocytes Monoclonal Antibody Revenue Market Share by Type (2021-2032)
5 Granulocytes Monoclonal Antibody Market by Application
  1. 5.1 Granulocytes Monoclonal Antibody Application Introduction
  2. 5.1.1 Immunofluorescence
  3. 5.1.2 Immunoprecipitation
  4. 5.1.3 ELISA
  5. 5.1.4 Flow Cytometry
  6. 5.1.5 Western Blot
  7. 5.1.6 Other
  8. 5.2 Global Granulocytes Monoclonal Antibody Sales by Application
  9. 5.2.1 Global Granulocytes Monoclonal Antibody Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Granulocytes Monoclonal Antibody Sales by Application (2021-2032)
  11. 5.2.3 Global Granulocytes Monoclonal Antibody Sales Market Share by Application (2021-2032)
  12. 5.3 Global Granulocytes Monoclonal Antibody Revenue by Application
  13. 5.3.1 Global Granulocytes Monoclonal Antibody Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Granulocytes Monoclonal Antibody Revenue by Application (2021-2032)
  15. 5.3.3 Global Granulocytes Monoclonal Antibody Revenue Market Share by Application (2021-2032)
6 Global Granulocytes Monoclonal Antibody Sales by Region
  1. 6.1 Global Granulocytes Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocytes Monoclonal Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global Granulocytes Monoclonal Antibody Sales by Region (2021-2026)
  4. 6.2.2 Global Granulocytes Monoclonal Antibody Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Granulocytes Monoclonal Antibody Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Granulocytes Monoclonal Antibody Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Granulocytes Monoclonal Antibody Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Granulocytes Monoclonal Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Granulocytes Monoclonal Antibody Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Granulocytes Monoclonal Antibody Revenue by Region
  1. 7.1 Global Granulocytes Monoclonal Antibody Revenue by Region
  2. 7.1.1 Global Granulocytes Monoclonal Antibody Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Granulocytes Monoclonal Antibody Revenue by Region (2021-2026)
  4. 7.1.3 Global Granulocytes Monoclonal Antibody Revenue by Region (2027-2032)
  5. 7.1.4 Global Granulocytes Monoclonal Antibody Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Granulocytes Monoclonal Antibody Revenue (2021-2032)
  8. 7.2.2 North America Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Granulocytes Monoclonal Antibody Revenue (2021-2032)
  11. 7.3.2 Europe Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Granulocytes Monoclonal Antibody Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Granulocytes Monoclonal Antibody Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Granulocytes Monoclonal Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbexa
  2. 8.1.1 Abbexa Company Information
  3. 8.1.2 Abbexa Business Overview
  4. 8.1.3 Abbexa Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbexa Granulocytes Monoclonal Antibody Product Portfolio
  6. 8.1.5 Abbexa Recent Developments
  7. 8.2 Assay Genie
  8. 8.2.1 Assay Genie Company Information
  9. 8.2.2 Assay Genie Business Overview
  10. 8.2.3 Assay Genie Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Assay Genie Granulocytes Monoclonal Antibody Product Portfolio
  12. 8.2.5 Assay Genie Recent Developments
  13. 8.3 Biomatik
  14. 8.3.1 Biomatik Company Information
  15. 8.3.2 Biomatik Business Overview
  16. 8.3.3 Biomatik Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biomatik Granulocytes Monoclonal Antibody Product Portfolio
  18. 8.3.5 Biomatik Recent Developments
  19. 8.4 Boster Biological Technology
  20. 8.4.1 Boster Biological Technology Company Information
  21. 8.4.2 Boster Biological Technology Business Overview
  22. 8.4.3 Boster Biological Technology Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boster Biological Technology Granulocytes Monoclonal Antibody Product Portfolio
  24. 8.4.5 Boster Biological Technology Recent Developments
  25. 8.5 CLOUD-CLONE CORP.
  26. 8.5.1 CLOUD-CLONE CORP. Company Information
  27. 8.5.2 CLOUD-CLONE CORP. Business Overview
  28. 8.5.3 CLOUD-CLONE CORP. Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CLOUD-CLONE CORP. Granulocytes Monoclonal Antibody Product Portfolio
  30. 8.5.5 CLOUD-CLONE CORP. Recent Developments
  31. 8.6 CUSABIO
  32. 8.6.1 CUSABIO Company Information
  33. 8.6.2 CUSABIO Business Overview
  34. 8.6.3 CUSABIO Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CUSABIO Granulocytes Monoclonal Antibody Product Portfolio
  36. 8.6.5 CUSABIO Recent Developments
  37. 8.7 Innovative Research
  38. 8.7.1 Innovative Research Company Information
  39. 8.7.2 Innovative Research Business Overview
  40. 8.7.3 Innovative Research Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Innovative Research Granulocytes Monoclonal Antibody Product Portfolio
  42. 8.7.5 Innovative Research Recent Developments
  43. 8.8 LifeSpan BioSciences, Inc
  44. 8.8.1 LifeSpan BioSciences, Inc Company Information
  45. 8.8.2 LifeSpan BioSciences, Inc Business Overview
  46. 8.8.3 LifeSpan BioSciences, Inc Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 LifeSpan BioSciences, Inc Granulocytes Monoclonal Antibody Product Portfolio
  48. 8.8.5 LifeSpan BioSciences, Inc Recent Developments
  49. 8.9 MyBiosource, Inc.
  50. 8.9.1 MyBiosource, Inc. Company Information
  51. 8.9.2 MyBiosource, Inc. Business Overview
  52. 8.9.3 MyBiosource, Inc. Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MyBiosource, Inc. Granulocytes Monoclonal Antibody Product Portfolio
  54. 8.9.5 MyBiosource, Inc. Recent Developments
  55. 8.10 ZodelBiotec Ltd.
  56. 8.10.1 ZodelBiotec Ltd. Company Information
  57. 8.10.2 ZodelBiotec Ltd. Business Overview
  58. 8.10.3 ZodelBiotec Ltd. Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ZodelBiotec Ltd. Granulocytes Monoclonal Antibody Product Portfolio
  60. 8.10.5 ZodelBiotec Ltd. Recent Developments
  61. 8.11 RayBiotech, Inc.
  62. 8.11.1 RayBiotech, Inc. Company Information
  63. 8.11.2 RayBiotech, Inc. Business Overview
  64. 8.11.3 RayBiotech, Inc. Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 RayBiotech, Inc. Granulocytes Monoclonal Antibody Product Portfolio
  66. 8.11.5 RayBiotech, Inc. Recent Developments
  67. 8.12 Thermo Fisher
  68. 8.12.1 Thermo Fisher Company Information
  69. 8.12.2 Thermo Fisher Business Overview
  70. 8.12.3 Thermo Fisher Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Thermo Fisher Granulocytes Monoclonal Antibody Product Portfolio
  72. 8.12.5 Thermo Fisher Recent Developments
  73. 8.13 Shanghai Korain Biotech Co., Ltd.
  74. 8.13.1 Shanghai Korain Biotech Co., Ltd. Company Information
  75. 8.13.2 Shanghai Korain Biotech Co., Ltd. Business Overview
  76. 8.13.3 Shanghai Korain Biotech Co., Ltd. Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Shanghai Korain Biotech Co., Ltd. Granulocytes Monoclonal Antibody Product Portfolio
  78. 8.13.5 Shanghai Korain Biotech Co., Ltd. Recent Developments
  79. 8.14 Wuhan Fine Biotech Co., Ltd.
  80. 8.14.1 Wuhan Fine Biotech Co., Ltd. Company Information
  81. 8.14.2 Wuhan Fine Biotech Co., Ltd. Business Overview
  82. 8.14.3 Wuhan Fine Biotech Co., Ltd. Granulocytes Monoclonal Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Wuhan Fine Biotech Co., Ltd. Granulocytes Monoclonal Antibody Product Portfolio
  84. 8.14.5 Wuhan Fine Biotech Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulocytes Monoclonal Antibody Value Chain Analysis
  2. 9.1.1 Granulocytes Monoclonal Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulocytes Monoclonal Antibody Production Mode & Process
  6. 9.2 Granulocytes Monoclonal Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulocytes Monoclonal Antibody Distributors
  9. 9.2.3 Granulocytes Monoclonal Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst